Dimensional Fund Advisors LP Acquires 831,146 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Dimensional Fund Advisors LP boosted its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO - Free Report) by 30.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,561,626 shares of the company's stock after purchasing an additional 831,146 shares during the quarter. Dimensional Fund Advisors LP owned about 1.70% of Allogene Therapeutics worth $7,586,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. grew its position in shares of Allogene Therapeutics by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,188,838 shares of the company's stock worth $2,532,000 after buying an additional 9,990 shares during the period. Gilead Sciences Inc. acquired a new stake in Allogene Therapeutics in the fourth quarter worth $2,464,000. Barclays PLC raised its holdings in shares of Allogene Therapeutics by 122.0% during the fourth quarter. Barclays PLC now owns 761,286 shares of the company's stock valued at $1,621,000 after purchasing an additional 418,313 shares during the period. Nordea Investment Management AB grew its stake in shares of Allogene Therapeutics by 2.1% in the 4th quarter. Nordea Investment Management AB now owns 460,641 shares of the company's stock valued at $986,000 after buying an additional 9,635 shares during the period. Finally, abrdn plc acquired a new position in Allogene Therapeutics during the 4th quarter worth approximately $776,000. 83.63% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ALLO shares. Royal Bank of Canada reaffirmed an "outperform" rating and set a $10.00 target price on shares of Allogene Therapeutics in a research report on Wednesday. Robert W. Baird dropped their price target on shares of Allogene Therapeutics from $12.00 to $9.00 and set an "outperform" rating on the stock in a research report on Wednesday. HC Wainwright cut their price target on shares of Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, March 19th. Piper Sandler cut their target price on Allogene Therapeutics from $9.00 to $7.00 and set an "overweight" rating on the stock in a research note on Wednesday. Finally, Citizens Jmp lowered Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $8.46.

Insider Activity at Allogene Therapeutics

In related news, CEO David D. Chang sold 46,668 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total transaction of $91,469.28. Following the sale, the chief executive officer now owns 5,276,569 shares of the company's stock, valued at approximately $10,342,075.24. This represents a 0.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders sold 61,757 shares of company stock worth $115,873. Corporate insiders own 13.20% of the company's stock.

Allogene Therapeutics Trading Down 15.7%

Shares of ALLO stock traded down $0.18 on Wednesday, hitting $0.95. 13,043,166 shares of the stock were exchanged, compared to its average volume of 3,371,740. The firm's 50 day moving average is $1.55 and its two-hundred day moving average is $1.95. Allogene Therapeutics, Inc. has a one year low of $0.87 and a one year high of $3.78. The firm has a market capitalization of $208.38 million, a PE ratio of -0.61 and a beta of 0.60.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.28) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.28). On average, sell-side analysts expect that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current year.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).